Abstract
Epithelial ovarian cancer (EOC) is known as the most lethal gynaecologic malignancy. The poor prognosis of EOC has been attributed to e.g., late diagnosis of the disease and to chemoresistance. Further, we are still missing biomarkers that may reliably predict prognosis or chemosensitivity of an individual patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
